Rhythm Pharmaceuticals (RYTM) return on equity (ROE)

Return on equity · fiscal 2025
-72.8%

Rhythm Pharmaceuticals (RYTM) earned a return on equity of -72.8% in fiscal 2025 (the year ended December 31, 2025). That is 85.6 percentage points higher than the -158.4% of fiscal 2024. Figures as of 17 Nov 2026, 19:10 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-72.8%
Change on fiscal 2024
+85.6 pts
Highest on record
-23.3%fiscal 2017
Lowest on record
-158.4%fiscal 2024
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Rhythm Pharmaceuticals return on equity (ROE), in more detail

Across the 9 fiscal years on record (2017–2025), the highest was -23.3% in fiscal 2017 and the lowest -158.4% in fiscal 2024. The fiscal 2025 figure is higher than in 38% of the 8 earlier fiscal years on record, whose median is -59.3%.

History · 9 fiscal years

Return on equity by fiscal year

Rhythm Pharmaceuticals return on equity (ROE), year by year

Rhythm Pharmaceuticals (RYTM) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-72.8% 85.6 pts up
2024-158.4% 49.6 pts down
2023-108.8% 40.3 pts down
2022-68.5% 44.0 pts down
2021-24.5% 56.0 pts up
2020-80.5% 30.4 pts down
2019-50.1% 20.0 pts down
2018-30.1% 6.8 pts down
2017-23.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Rhythm Pharmaceuticals and comparable companies
CompanyReturn on equityFiscal year
Rhythm Pharmaceuticals RYTM-72.8%2025
Alkermes ALKS13.3%2025
PACS Group PACS20.2%2025
Kiniksa Pharmaceuticals International KNSA10.4%2025
ImmunityBio IBRX-130.7%2019
Cytokinetics CYTK-88.3%2021

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RYTM

Rhythm Pharmaceuticals, figure by figure

Rhythm Pharmaceuticals (RYTM) overview: price, valuation and scorecardAll health care companies by market value

Rhythm Pharmaceuticals return on equity (ROE): questions and answers

What is Rhythm Pharmaceuticals's return on equity?

Rhythm Pharmaceuticals (RYTM) earned a return on equity of -72.8% in fiscal 2025 (the year ended December 31, 2025). That is 85.6 percentage points higher than the -158.4% of fiscal 2024.

Is Rhythm Pharmaceuticals's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 38% of the 8 earlier fiscal years on record, whose median is -59.3%.

What are the highest and lowest return on equity figures on record for Rhythm Pharmaceuticals?

Across the 9 fiscal years on record (2017–2025), the highest was -23.3% in fiscal 2017 and the lowest -158.4% in fiscal 2024.

How is Rhythm Pharmaceuticals's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Rhythm Pharmaceuticals (RYTM) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/RYTM/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.